Title:    Pap Cytology, HPV Testing, and the importance of Co-testing in Cervical Cancer Screening

3rd October 2021 (Sunday) 11:00 am – 12:00 noon 

(1) How a Design of Human Papillomavirus Tests Can Impact on Safety and Efficacy of HPV Tests in Cervical Cancer Screening 
By Damon Getman, PhD 
Sr. Principal Scientist & Director, 
Medical & Scientific Affairs, Hologic 

(2) The Evolution of Cervical Cancer Screening Guidelines, HPV Vaccination Trends in Cervical Cancer incidence and the value of Co-testing in Cervical Cancer Screening 
By Alison D Cowan, MD, MS, FACOG 
Medical Director, Diagnostic Solutions Division, Hologic 
Obstetrician & Gynecologist, University of Colorado Health
Moderator:     Dr. KY Tse, Honorary Secretary, OGSHK
Target audience:  Registered medical practitioners and nurses
CME / CNE:     pending approval

Since the introduction of Pap Smear by Dr. Papanicolaou in 1940s, the cervical cancer incidence rate has dropped tremendously worldwide. In Hong Kong, the cervical cancer is the seventh commonest cancer among women in 2018, but it remains higher than developed Western economies. In addition, human papillomavirus (HPV) vaccine is offered to protect against several types of high-risk HPV. As a result, which screening strategy can maximize the benefits of screening while minimizing the potential harms of screening?